Tous Actualités
Suivre
Abonner LifeWatch AG

LifeWatch AG

EANS-Adhoc: LifeWatch announces comprehensive cardiac monitoring suite in a technology breakthrough using a single device platform (with document)

Un document

--------------------------------------------------------------------------------
  ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
  distribution. The issuer is solely responsible for the content of this
  announcement.
--------------------------------------------------------------------------------
New Products/LifeWatch AG

08.03.2012

Neuhausen am Rheinfall/Switzerland - In an industry first and exclusive
development, LifeWatch AG (SIX Swiss Exchange:LIFE), a leading wireless
monitoring and technology company in the U.S., has announced a comprehensive
cardiac monitoring suite embodied in a single technology platform. This software
defined medical device encompasses the capabilities of Holter, CEM (auto
trigger/auto send and patient activation) as well as the Company's leading and
proprietary ACT Ambulatory Cardiac Telemetry product and service. The Company
has conducted and concluded a regulatory review to assure compliance with FDA
regulations on this cleared medical device with the proper indications for use.

You will find a PDF-version of this press release at the end of this message.   

"The Elite service addresses many of the significant needs identified to
LifeWatch by our users over a several year period of time. It is an
acknowledgement to these customers that we have listened to their concerns and
issues and according to them, responded appropriately to their needs," stated
Dr. Yacov Geva, Chairman and CEO of LifeWatch AG, "The Elite service is arguably
the most sophisticated outpatient cardiac monitoring service and technology in
the market today". 

A programmable feature switches the device from the advanced ACT III ambulatory
ECG telemetry system (with 3-channel ECG and optional 24-48 hour Holter
reporting), to a sophisticated Auto- Detect/Auto-Send 3-channel ECG cardiac
monitoring system. This state-of-the-art technology also enables a streamlined
enrollment process, better and easier onsite inventory control  for customers
and delivers additional customer efficiencies by eliminating the confusing
panoply of inconsistent service and technology choices faced by physicians in
busy practices.    

The Elite service builds on LifeWatch's already fielded ACT Ex extended service
which allows a physician to order a Holter test prior to determining the need
for the ACT Telemetry service. The ACT Ex has improved patient compliance as the
patient can seamlessly transition from Holter to ambulatory cardiac telemetry
if, after 48 hours of monitoring, there has not been a diagnostic finding and
the physician wishes to have the patient monitored for an extended period of
time without having to come back to the office and switch out devices. 

The addition of the auto trigger/auto send capability of a cardiac event monitor
to the ACT platform, closes the loop for the physician by adding this capability
to his diagnostic arsenal. If the patient leaves the office with the ACT service
and it is discovered, for instance, that the patient didn't meet the criteria
for the ACT service, instead of contacting the patient and having them return to
the practice to get fitted with another device, a software change is made
transparently to the patient and the service now becomes an auto trigger/auto
send CEM service. The Elite service makes simplicity an attribute of the present
market situation and allows the physician to concentrate on practicing medicine
without worrying about monitoring.

It is estimated that approximately 70% of present LifeWatch customers will
benefit from this additional capability.


About LifeWatch AG:

LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss
Exchange (LIFE), Switzerland, is the leading healthcare technology and solution
company, specializing in advanced telehealth systems and wireless remote patient
monitoring services. LifeWatch services cater to individuals, ranging from
high-risk and chronically ill patients, to consumers of health and wellness
products. LifeWatch has subsidiaries in the United States, the Netherlands,
Japan, the United Kingdom, Switzerland and Israel. LifeWatch AG is the parent
company of LifeWatch Services Inc., a leading US-based cardiac monitoring
service provider, and manufacturer of telecardiology products. LifeWatch is also
introducing a new program for Home Sleep Testing of Obstructive Sleep Apnea
(OSA) patients under the brand name NiteWatch. For additional information,
please visit www.lifewatch.com.

Sign-up for customized E-mail alerts and documentation requests is available at 
http://production.investis.com/lifewatch/alert-service/

This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position,
business strategy and plans and objectives for future operations, are
forward-looking statements. The words "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "expect" and similar expressions are
intended to identify forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and projections about
future events and financial trends that it believes may affect the financial
condition, results of operations, business strategy, short term and long term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based only on
data available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise. 

THIS PRESS RELEASE IS NOT BEING ISSUED IN THE UNITED STATES OF AMERICA AND
SHOULD NOT BE DISTRIBUTED TO UNITED STATES PERSONS OR PUBLICATIONS WITH A
GENERAL CIRCULATION IN THE UNITED STATES. THIS PRESS RELEASE DOES NOT CONSTITUTE
AN OFFER OF SECURITIES OF LIFEWATCH AG OR ANY OF ITS SUBSIDIARIES FOR SALE IN
THE UNITED STATES OR AN INVITATION TO SUBSCRIBE FOR OR PURCHASE ANY SECURITIES
OF LIFEWATCH AG OR ITS SUBSIDIARIES IN THE UNITED STATES. IN ADDITION, THE
SECURITIES OF LIFEWATCH AG AND ITS SUBSIDIARIES HAVE NOT BEEN REGISTERED UNDER
THE UNITED STATES SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR DELIVERED
WITHIN THE UNITED STATES OR TO U.S. PERSONS ABSENT REGISTRATION UNDER OR AN
APPLICABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE UNITED STATES
SECURITIES LAWS.  ANY PUBLIC OFFERING OF SECURITIES TO BE MADE IN THE UNITED
STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM LIFEWATCH
AG OR ITS SUBSIDIARIES, AS APPLICABLE, AND WILL CONTAIN DETAILED INFORMATION
ABOUT THE ISSUER AND ITS MANAGEMENT AS WELL AS FINANCIAL STATEMENTS OF THE
ISSUER.

Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/Rd8E7zsy

Further inquiry note:
Sensus Investor and Public Relations, Zürich:
Tel +41 43 366 55 11 | Fax +41 43 366 55 12 | Email  lifewatch@sensus.ch

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


Attachments with Announcement:
----------------------------------------------
http://resources.euroadhoc.com/us/Rd8E7zsy


issuer:      LifeWatch AG
             Rundbuckstrasse 6
             CH-8212 Neuhausen am Rheinfall
phone:       +41 52 632 00 50
FAX:         +41 52 632 00 51
mail:         users@lifewatch.com
WWW:      www.lifewatch.com
sector:      Healthcare Providers
ISIN:        CH0012815459
indexes:     SPI, SPIEX
stockmarkets: free trade: Berlin, Open Market / XETRA: Frankfurt, Main Standard:
             SIX Swiss Exchange 
language:   English

Plus de actualités: LifeWatch AG
Plus de actualités: LifeWatch AG